Abstract
Background The prevalence of myopia in Scandinavia seems to differ from other parts of the world and the reasons remain poorly investigated. The current study investigated the incidence of myopia, myopic shift, and associated risk factors in Swedish schoolchildren. This study also investigated the development of refractive error under the effect of COVID-19 restrictions.
Methods This longitudinal study was conducted between Jan-2019 and June-2021 in which a cohort of Swedish schoolchildren aged 8-16 years were recruited. Myopia was defined as spherical equivalent refraction (SER) -0.50D. Myopic shift was defined as a minimum change in SER of -0.50D between each visit. Cumulative incidence (CIN) and incidence rate (IRA) were computed. Cox-regression and linear mixed models were used to modulate myopic shift and changes in SER.
Results The study enrolled 128 participants, 86% Caucasian, 70 females, mean age 12.0 years (SD=2.4). The CIN of myopia during the two-years follow-up was 5.5%, IRA of myopia was 3.2 cases per 100 person-years. The CIN of myopic shift during the two-years was 21.0%, IRA of myopic shift was 12.4 cases per 100 person-years. Cox regression revealed that the probability of myopic shift reduced with age and increased with axial length/corneal-curvature ratio. Myopic children at the baseline and children with two myopic parents showed a significant faster-paced negative SER change over time. Changes in SER during the first year of the study were more marked than changes during the second year that coincided with the Covid pandemic.
Conclusions In the current study the incidence of myopia and myopic shift was low when compared with countries in East Asia. Parental myopia remains a critical factor to consider when predicting myopia progression. Progression of myopia was unaffected by restrictions imposed during COVID-19 in Sweden. In addition to ethnicity, lifestyle and adequate educational pressure might be factors keeping prevalence of myopia under control in Scandinavia. Further studies to investigate these hypotheses are warranted.
What is already known on this topic The rate of myopia is increasing in many regions of the world, and the recent lockdowns caused by the COVID-19 pandemic has exacerbated this problem. The highest rates of myopia are from East Asia and are in sharp contrast to the low levels reported from Scandinavia. There is a lack of studies exploring the incidence of myopia in the Scandinavian population. We conducted this study to identify the incidence of myopia among Swedish children and to determine whether the COVID-19 pandemic had any significant effects.
What this study adds This study is the first to report the incidence of myopia and the myopic shift in Scandinavia. The study results showed that myopia and myopic shift were low compared to other parts of the globe. Myopia progression was not affected by the pandemic, perhaps due to Sweden’s avoidance of severe restrictions during the outbreak. Parental myopia was the significant risk factor for the progression of myopia in this cohort of Swedish school children.
How this study might affect research, practice, or policy It is clear from this study’s results that parental myopia is a risk factor for myopia and is an influential predictor to consider in clinical trials that evaluate interventions to slow down the progression of myopia. Outdoor lifestyle and less educational pressure at young ages may be contributing factors to the low prevalence and incidence of myopia in Swedish children.
Synopsis Incidence of myopia was low in Swedish schoolchildren despite COVID-19 pandemic and the associated risk factor was parental myopia and younger age.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/33689658/
Funding Statement
This study was supported by Specsavers Sweden AB, the faculty of Health and Life Sciences, Linnaeus University, and Brien Holden Vision Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received ethics approval from The Regional Committee for Medical Research Ethics in Linkoping (Dnr 2018/423-31).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Introduction first paragraph Discussion first and sixth paragraph
Data Availability
All data produced in the present study are available upon reasonable request to the authors
